Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUNX1 | Q01196 | 8/20 | 0.84 |
| ▸ | CBFB | Q13951 | 4/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ATP4A | P20648 | 3/20 | 0.42 |
| ▸ | ATP4B | P51164 | 3/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525962 | 0.85 | RUNX1 (0.62) | RUNX1CBFBTRPV1 | |
| SCHEMBL17525964 | 0.81 | RUNX1 (0.83) | RUNX1CBFBTRPV1AMY1AKDM4E | |
| SCHEMBL179101 | 0.78 | CBFB (0.63) | RUNX1CBFBTRPV1 | |
| SCHEMBL6871855 | 0.77 | RUNX1 (0.52) | RUNX1ATP4AATP4BCYP2C9KDM4E | |
| SCHEMBL27990381 | 0.77 | RUNX1 (0.52) | RUNX1CBFBATP4AATP4BIGF1R | |
| SCHEMBL179102 | 0.77 | CBFB (0.82) | RUNX1CBFBTRPV1 | |
| SCHEMBL11903505 | 0.77 | RUNX1 (0.57) | RUNX1CBFBTRPV1AMY1AKDM4E | |
| SCHEMBL23988282 | 0.77 | RUNX1 (0.52) | RUNX1ATP4AATP4BCYP2C9KDM4E | |
| SCHEMBL11903647 | 0.76 | TRPV1 (0.62) | RUNX1CBFBTRPV1KDM4EALDH1A1 | |
| SCHEMBL179096 | 0.76 | CBFB (0.63) | RUNX1CBFBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-06-16 | — | — | US | disclosed |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200377888-A1 | RUNX1 INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION | MASSACHUSETTS EYE AND EAR INFIRMARY | 2020-12-03 | — | — | US | disclosed |
| US-20200375899-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY | MASSACHUSETTS EYE AND EAR INFIRMARY | 2020-12-03 | — | — | US | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190350961-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-11-21 | — | — | US | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016025744-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375899-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY | RUNX1, CBFB, IKZF1 | RUNX1 1/4885CBFB 2/4885TRPV1 4258/4885 |
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | RUNX1 1/4885CBFB 2/4885TRPV1 2944/4885 |
| US-20200377888-A1 | RUNX1 INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION | RUNX1, CXCL12, MITF | RUNX1 1/4885CBFB 7/4885TRPV1 3577/4885 |
| US-20190350961-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | RUNX1 183/4885CBFB 374/4885TRPV1 4502/4885 |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | VEGFA, PGF, FLT4 | RUNX1 183/4885CBFB 374/4885TRPV1 4502/4885 |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | RUNX1, CXCL12, MITF | RUNX1 1/4885CBFB 7/4885TRPV1 3577/4885 |
| US-10562890-B2 | Cancer therapeutics | RUNX1, CBFB, MCL1 | RUNX1 1/4885CBFB 2/4885TRPV1 2944/4885 |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | RUNX1 183/4885CBFB 374/4885TRPV1 4502/4885 |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | RUNX1, CBFB, IKZF1 | RUNX1 1/4885CBFB 2/4885TRPV1 4237/4885 |
| US-11583497-B2 | Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery | RUNX1, CBFB, IKZF1 | RUNX1 1/4885CBFB 2/4885TRPV1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.